FNYS
BCRX icon

First New York Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

First New York Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-994
Closed -$7K – 285
2013
Q3 		$7K Buy
+994
New +$5.04K ﹤0.01% 335

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First New York Securities's BCRX Position: Q4 2013 in Review

First New York Securities sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2013, closing a stake of 994 shares — an estimated $7K sold.

First New York Securities first reported a position in BCRX in Q3 2013 and held it in 1 quarter. The position peaked at $7K in Q3 2013. 75 funds tracked by Wall St. Rank hold BCRX as of Q4 2013.

  • First New York Securities reported no remaining BioCryst Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • First New York Securities sold 994 BioCryst Pharmaceuticals shares in Q4 2013, an estimated $7K.
  • First New York Securities first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • First New York Securities's BioCryst Pharmaceuticals position peaked at $7K in Q3 2013.
  • 75 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2013.

Based on First New York Securities's 13F filing for Q4 2013, filed 12 Feb 2014.